Masimo Co. (NASDAQ:MASI) Shares Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP grew its holdings in Masimo Co. (NASDAQ:MASI) by 23.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,394,056 shares of the medical equipment provider’s stock after buying an additional 262,370 shares during the quarter. Masimo comprises 0.8% of Westfield Capital Management Co. LP’s investment portfolio, making the stock its 23rd biggest holding. Westfield Capital Management Co. LP owned 2.60% of Masimo worth $185,869,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of MASI. NBC Securities Inc. lifted its holdings in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the period. HHM Wealth Advisors LLC lifted its holdings in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 573 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MASI has been the subject of several recent analyst reports. Piper Sandler raised their price target on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Wells Fargo & Company lifted their price objective on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. BTIG Research lifted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Finally, Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $167.00.

Masimo Stock Performance

Masimo stock opened at $172.96 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a fifty day moving average of $143.48 and a two-hundred day moving average of $128.00. The company has a market capitalization of $9.26 billion, a price-to-earnings ratio of 119.28 and a beta of 0.97. Masimo Co. has a fifty-two week low of $91.60 and a fifty-two week high of $174.34.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 earnings per share. On average, analysts anticipate that Masimo Co. will post 4.04 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.